首页> 外国专利> ALPHA-1 PROTEINASES INHIBITOR TO DELAY THE BEGINNING OR PROGRESSION OF PULMONARY EXCESSIONS

ALPHA-1 PROTEINASES INHIBITOR TO DELAY THE BEGINNING OR PROGRESSION OF PULMONARY EXCESSIONS

机译:ALPHA-1蛋白酶可延缓肺动脉扩张的开始或进展

摘要

1. A method of delaying the onset or reducing the progression of one or more symptoms associated with pulmonary exacerbations in a subject in need thereof, comprising administering to the subject an effective amount of A1PI by inhalation. 2. The method according to claim 1, wherein the A1PI is aerosolized. 3. The method according to claim 1, wherein the A1PI is administered using an inhaler. 4. The method according to claim 1, wherein the A1PI is administered at least once a day. The method according to claim 1, wherein the effective amount of A1PI is from about 25 mg to about 750 mg of A1PI per day. The method according to claim 1, wherein the effective amount of A1PI is from about 0.5 mg / kg / day to about 15 mg / kg / day. The method according to claim 1, wherein the age of the subject who needs it is at least 12 years. The method according to claim 1, wherein exacerbations of pulmonary diseases are associated with fibrocystic degeneration, COPD, AATD (A1PI deficiency), emphysema, asthma, mycobacterial infection, pneumonia, bronchiectasis, or chronic bronchitis. 9. The method in accordance with paragraph 1, where pulmonary exacerbations are associated with increased severity of exacerbations; increased frequency of exacerbations; decreased lung function; reduced levels of FEV; increased loss of lung tissue; reduced A1PI levels; elevated levels of pulmonary elastase; frequent pulmonary infections; increased bacterial load of the lungs or increased cardiac arrhythmia. 10. The method according to claim 1, wherein the A1PI is a recombinant A1PI. 11. The method according to claim 1, wherein the A1PI is purified using a method for purification of A1PI from an aqueous solution
机译:1.一种在有需要的受试者中延迟与一种或多种与肺部恶化相关的症状的发作或减轻其进展的方法,其包括通过吸入向所述受试者施用有效量的A1PI。 2.根据权利要求1所述的方法,其中所述AlPI被雾化。 3.根据权利要求1的方法,其中所述AlPI是使用吸入器施用的。 4.根据权利要求1所述的方法,其中所述A1PI每天至少施用一次。 2.根据权利要求1的方法,其中A1PI的有效量为每天约25mg至约750mg A1PI。 2.根据权利要求1所述的方法,其中所述AlPI的有效量为约0.5mg / kg /天至约15mg / kg /天。 2.根据权利要求1所述的方法,其中,需要该治疗的受试者的年龄为至少12岁。 2.根据权利要求1所述的方法,其中,肺部疾病的恶化与纤维囊性变性,COPD,AATD(A1PI缺乏症),肺气肿,哮喘,分枝杆菌感染,肺炎,支气管扩张或慢性支气管炎有关。 9.根据第1款的方法,其中肺部加重与加重的严重程度有关;加剧发作的频率;肺功能下降;降低FEV水平;肺组织损失增加;降低了A1PI水平;肺弹性蛋白酶水平升高;频繁的肺部感染;肺部细菌负荷增加或心律不齐增加。 10.根据权利要求1的方法,其中所述A1PI是重组A1PI。 11.根据权利要求1的方法,其中使用从水溶液中纯化A1PI的方法纯化A1PI。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号